Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma

Gang Ji,Qi Yang,Song Wang,Xiaolong Yan,Qiuxiang Ou,Li Gong,Jinbo Zhao,Yongan Zhou,Feng Tian,Jie Lei,Xiaorong Mu,Jian Wang,Tao Wang,Xiaoping Wang,Jianyong Sun,Jipeng Zhang,Chenghui Jia,Tao Jiang,Ming-gao Zhao,Qiang Lu

DOI: https://doi.org/10.1186/s13073-024-01320-9

IF: 15.266

2024-04-02

Genome Medicine

Abstract:Abstract Background The efficacy of neoadjuvant chemo-immunotherapy (NAT) in esophageal squamous cell carcinoma (ESCC) is challenged by the intricate interplay within the tumor microenvironment (TME). Unveiling the immune landscape of ESCC in the context of NAT could shed light on heterogeneity and optimize therapeutic strategies for patients. Methods We analyzed single cells from 22 baseline and 24 post-NAT treatment samples of stage II/III ESCC patients to explore the association between the immune landscape and pathological response to neoadjuvant anti-PD-1 combination therapy, including pathological complete response (pCR), major pathological response (MPR), and incomplete pathological response (IPR). Results Single-cell profiling identified 14 major cell subsets of cancer, immune, and stromal cells. Trajectory analysis unveiled an interesting link between cancer cell differentiation and pathological response to NAT. ESCC tumors enriched with less differentiated cancer cells exhibited a potentially favorable pathological response to NAT, while tumors enriched with clusters of more differentiated cancer cells may resist treatment. Deconvolution of transcriptomes in pre-treatment tumors identified gene signatures in response to NAT contributed by specific immune cell populations. Upregulated genes associated with better pathological responses in CD8 + effector T cells primarily involved interferon-gamma (IFNγ) signaling, neutrophil degranulation, and negative regulation of the T cell apoptotic process, whereas downregulated genes were dominated by those in the immune response-activating cell surface receptor signaling pathway. Natural killer cells in pre-treatment tumors from pCR patients showed a similar upregulation of gene expression in response to IFNγ but a downregulation of genes in the neutrophil-mediated immunity pathways. A decreased cellular contexture of regulatory T cells in ESCC TME indicated a potentially favorable pathological response to NAT. Cell–cell communication analysis revealed extensive interactions between CCL5 and its receptor CCR5 in various immune cells of baseline pCR tumors. Immune checkpoint interaction pairs, including CTLA4-CD86, TIGIT-PVR, LGALS9-HAVCR2, and TNFSF4-TNFRSF4, might serve as additional therapeutic targets for ICI therapy in ESCC. Conclusions This pioneering study unveiled an intriguing association between cancer cell differentiation and pathological response in esophageal cancer patients, revealing distinct subgroups of tumors for which neoadjuvant chemo-immunotherapy might be effective. We also delineated the immune landscape of ESCC tumors in the context of clinical response to NAT, which provides clinical insights for better understanding how patients respond to the treatment and further identifying novel therapeutic targets for ESCC patients in the future.

genetics & heredity

What problem does this paper attempt to address?

### Problems Addressed by the Paper

This paper primarily explores the changes in the immune microenvironment at the single-cell level in patients with esophageal squamous cell carcinoma (ESCC) after receiving neoadjuvant chemo-immunotherapy (NAT) and its relationship with pathological response.

#### Specific Issues:
1. **Changes in the immune landscape within the tumor microenvironment**: The study aims to reveal the changes in the composition and function of immune cells at the single-cell level in ESCC patients before and after NAT treatment.
2. **Relationship between cancer cell differentiation and pathological response**: By analyzing cancer cell populations with different degrees of differentiation, the study explores their impact on the pathological response to NAT treatment.
3. **Identification of immune cell markers**: The study identifies gene expression characteristics of specific immune cell populations before and after NAT treatment to find potential biomarkers.
4. **Intercellular communication networks**: The study investigates the interactions between different immune cells and their mechanisms of action during NAT treatment.

#### Main Findings:
- **Differentiation degree and treatment effect**: The study found that less differentiated cancer cell populations are associated with better pathological responses, while more differentiated cancer cell populations may be resistant to treatment.
- **Changes in immune cell function**: Upregulated genes in CD8+ effector T cells are mainly involved in the interferon-γ (IFNγ) signaling pathway, neutrophil degranulation, and negative regulation of T cell apoptotic processes; downregulated genes are primarily concentrated in the cell surface receptor signaling pathway involved in immune response activation.
- **Role of NK cells**: NK cells in patients with complete pathological response (pCR) exhibit similar gene upregulation in IFNγ response but downregulation in genes involved in neutrophil-mediated immune response.
- **Intercellular communication analysis**: In baseline pCR tumor samples, there is extensive interaction between CCL5 and its receptor CCR5 among various immune cells, suggesting these molecules as potential additional therapeutic targets.

In summary, this study uses single-cell sequencing technology to reveal the dynamic changes in the immune microenvironment of ESCC patients after NAT treatment and provides new insights for optimizing treatment strategies.